Cannabis is the most used “illicit” drug in the world. In the United States, cannabis remains a Schedule I substance under the Controlled Substance Act. Since the different states in the US have legalized cannabis, its use has not only increased in general population but also among transplant recipients. 7 US States including Arizona have legislation prohibiting denial of transplant listing based on “medicine” cannabis use. Cannabis use is associated with reduced access to kidney transplantation and an increased risk of acute rejection post-transplant. Data regarding the impact of cannabis use on liver transplant (LT) outcomes is limited.

Our group investigated outcomes of adult LT patients who are current cannabis users (CCU, evidence of use within the past 18), remote cannabis users (RCU, history of use over 18 months ago), and cannabis non-users (CNU, lifetime non-use).

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.